THE ROLE OF SODIUM–GLUCOSE COTRANSPORTER-2 (SGLT2) INHIBITORS IN REDUCING THE RISK OF CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS : A SYSTEMATIC REVIEW OF RANDOMIZED CONTROLLED TRIALS AND PRIMARY STUDIES
The International Journal of Medical Science and Health Research · 07.08.2026 · 48 (5) · 135-230
DOI: 10.70070/dver3926 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift The International Journal of Medical Science and Health Research, online erschienen am 07.08.2026. Verfasst von Diani Nur Pathona. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Introduction
Type 2 diabetes mellitus (T2DM) confers a two- to four-fold excess risk of atherosclerotic cardiovascular disease, heart failure, and cardiovascular death. Sodium-glucose cotransporter-2 (SGLT2) inhibitors unexpectedly demonstrated cardiovascular benefit in dedicated cardiovascular outcome trials (CVOTs). This systematic review quantified the effect of SGLT2 inhibition across the full spectrum of cardiovascular events in T2DM patients.
Methods
A systematic review was performed per PRISMA 2020 guidelines. Eligible studies were phase III/IV randomized, placebo-controlled trials of SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin, ertugliflozin, sotagliflozin) enrolling adults with T2DM, with adjudicated cardiovascular endpoints and ≥6 months follow-up. Two reviewers independently screened, extracted data, and appraised risk of bias using Cochrane RoB 2. Certainty was rated using GRADE. Pooled estimates used generic inverse-variance random-effects meta-analysis.
Results
Twenty-one reports (17 distinct trials; 105,000 participants) met inclusion criteria. Pooled hazard ratios demonstrated: three-point MACE 0.89 (95% CI 0.84–0.94; p
Zitieren
APA
Pathona, D. N. (2026). THE ROLE OF SODIUM–GLUCOSE COTRANSPORTER-2 (SGLT2) INHIBITORS IN REDUCING THE RISK OF CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS : A SYSTEMATIC REVIEW OF RANDOMIZED CONTROLLED TRIALS AND PRIMARY STUDIES. The International Journal of Medical Science and Health Research, 48(5), 135-230. https://doi.org/10.70070/dver3926
Vancouver
Pathona DN. THE ROLE OF SODIUM–GLUCOSE COTRANSPORTER-2 (SGLT2) INHIBITORS IN REDUCING THE RISK OF CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS : A SYSTEMATIC REVIEW OF RANDOMIZED CONTROLLED TRIALS AND PRIMARY STUDIES. The International Journal of Medical Science and Health Research. 2026;48(5):135-230. doi:10.70070/dver3926
BibTeX
@article{Pathona2026,
author = {Pathona, Diani Nur},
title = {THE ROLE OF SODIUM–GLUCOSE COTRANSPORTER-2 (SGLT2) INHIBITORS IN REDUCING THE RISK OF CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS : A SYSTEMATIC REVIEW OF RANDOMIZED CONTROLLED TRIALS AND PRIMARY STUDIES},
journal = {The International Journal of Medical Science and Health Research},
year = {2026},
volume = {48},
number = {5},
pages = {135--230},
doi = {10.70070/dver3926}
}
EUVIMED